We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+11.35%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$81.6B
AUM Growth
+$7.7B
(+10%)
Cap. Flow
+$798M
Cap. Flow
% of AUM
0.98%
Top 10 Holdings %
Top 10 Hldgs %
23.85%
Holding
3,095
New
53
Increased
1,513
Reduced
1,408
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$65.3M |
| 2 |
Amazon
AMZN
|
+$50M |
| 3 |
Tesla
TSLA
|
+$30.5M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$26.6M |
| 5 |
EPAM Systems
EPAM
|
+$26.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KSU
Kansas City Southern
KSU
|
+$39.1M |
| 2 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$31.2M |
| 3 |
XEC
CIMAREX ENERGY CO
XEC
|
+$23.4M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$21.9M |
| 5 |
SBNY
Signature Bank
SBNY
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.54% |
| 2 | Financials | 13.15% |
| 3 | Healthcare | 12.95% |
| 4 | Consumer Discretionary | 12.27% |
| 5 | Industrials | 8.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
Pliant Therapeutics
PLRX
$65M
| $302K | ﹤0.01% |
22,344
-416
| -2% | -$6.61K |
|
2702
Apyx Medical
APYX
$171M
| $301K | ﹤0.01% |
23,459
-347
| -1% | -$4.85K |
|
2703
Pure Cycle
PCYO
$261M
| $301K | ﹤0.01% |
20,634
-387
| -2% | -$5.8K |
|
2704
Nkarta
NKTX
$172M
| $300K | ﹤0.01% |
19,569
-508
| -3% | -$8.71K |
|
2705
Blue Ridge Bankshares
BRBS
$332M
| $299K | ﹤0.01% |
16,715
-315
| -2% | -$5.72K |
|
2706
Caribou Biosciences
CRBU
$164M
| $298K | ﹤0.01% |
19,725
+2,126
| +12% | +$41.3K |
|
2707
Matrix Service
MTRX
$335M
| $298K | ﹤0.01% |
39,691
-37,516
| -49% | -$353K |
|
2708
South Plains Financial
SPFI
$841M
| $297K | ﹤0.01% |
10,697
-200
| -2% | -$5.2K |
|
2709
Teekay Tankers
TNK
$2.68B
| $297K | ﹤0.01% |
27,225
-533
| -2% | -$6.75K |
|
2710
Lineage Cell Therapeutics
LCTX
$278M
| $295K | ﹤0.01% |
120,434
+1,711
| +1% | +$4K |
|
2711
MediaAlpha
MAX
$821M
| $295K | ﹤0.01% |
19,094
-545
| -3% | -$9.09K |
|
|
EWCZ
2712
DELISTED
European Wax Center
EWCZ
| $294K | ﹤0.01% |
9,699
+2,225
| +30% | +$63.1K |
|
2713
Bioventus
BVS
$1.19B
| $292K | ﹤0.01% |
+20,145
| New | +$286K |
|
2714
Lifetime Brands
LCUT
$211M
| $291K | ﹤0.01% |
18,242
-456
| -2% | -$7.87K |
|
|
VLDR
2715
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
| $291K | ﹤0.01% |
62,748
-3,132
| -5% | -$18.3K |
|
2716
CytomX Therapeutics
CTMX
$754M
| $290K | ﹤0.01% |
66,948
-985
| -1% | -$5.77K |
|
2717
EverQuote
EVER
$906M
| $289K | ﹤0.01% |
18,449
+125
| +0.7% | +$1.91K |
|
2718
Zevra Therapeutics
ZVRA
$686M
| $289K | ﹤0.01% |
33,231
+506
| +2% | +$4.51K |
|
2719
Enact Holdings
ACT
$6.73B
| $288K | ﹤0.01% |
+13,912
| New | +$301K |
|
2720
Village Super Market
VLGEA
$639M
| $287K | ﹤0.01% |
12,290
-154
| -1% | -$3.45K |
|
|
ASXC
2721
DELISTED
Asensus Surgical, Inc.
ASXC
| $287K | ﹤0.01% |
258,473
-19,812
| -7% | -$30.6K |
|
2722
Nature's Sunshine
NATR
$288M
| $282K | ﹤0.01% |
15,250
-515
| -3% | -$8.74K |
|
|
EPZM
2723
DELISTED
Epizyme, Inc
EPZM
| $282K | ﹤0.01% |
112,716
-1,123
| -1% | -$4.41K |
|
|
ICVX
2724
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $281K | ﹤0.01% |
12,289
+264
| +2% | +$6.82K |
|
|
MRLN
2725
DELISTED
Marlin Business Services Corp
MRLN
| $281K | ﹤0.01% |
12,057
-147
| -1% | -$3.35K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, RhumbLine Advisers held 3,095 positions worth $81.6B, up 10% from $73.9B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Trading was light in Q4 2021: portfolio turnover was 4.4%. RhumbLine Advisers opened 53 new positions and exited 84, leaving the 3,095-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2021 buy was Rivian: 125,331 shares worth $13M.
- RhumbLine Advisers added most to Microsoft in Q4 2021, an estimated $65.3M increase.
- RhumbLine Advisers's biggest Q4 2021 reduction was Berkshire Hathaway Class B, cutting an estimated $21.9M.
- RhumbLine Advisers fully exited Kansas City Southern in Q4 2021, selling an estimated $39.1M.
- RhumbLine Advisers's ten largest holdings make up 24% of its $81.6B portfolio in Q4 2021.
- RhumbLine Advisers opened 53 new positions and closed 84 in Q4 2021.
- RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $81.6B.
Based on RhumbLine Advisers's 13F filing for Q4 2021, filed 10 Feb 2022.